EN DE
Watch AlzeCure Pharma for free: we tell you when fair value or trend changes.
Data-driven stock valuation

AlzeCure Pharma (ALZCUR) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of AlzeCure Pharma stock SEK 4.54, price SEK 6.46, that is 29.7% below the price, quality 53 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare SE · ISIN SE0010133785

AP AlzeCure Pharma logo Thin data Nov 10, 2026

AlzeCure Pharma

ALZCUR · ST
Solid, but expensive

Our calculation puts a fair price 30% below what the stock costs today.

Highly profitable · 31.6% net margin (TTM)
63% return on equity.
Quality 53/100
Mixed vs. peers (6/11)
Wide moat 75/100 · thin data
Fair value kr 4.54 · Overvalued
Weak Growth
Negative free cash flow
Thin data
Estimate
Watch AlzeCure Pharma for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

kr 8.44 kr 0.9240 Fair Value kr 4.54 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range kr 0.9240 – kr 8.44 · fair‑value band kr 3.41 – kr 5.68 · the kr 6.46 price screens above the kr 4.54 fair value. As of Nov 10, 2026.

Follow AlzeCure Pharma in your weekly email

Every Wednesday you see whether AlzeCure Pharma is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

AlzeCure Pharma AB (publ) operates as a pharmaceutical company that develops small-molecule drug therapies for the treatment of severe diseases and conditions that affect the central nervous system.

Show moreShow less

The company is involved in the development of drug candidates based on the NeuroRestore, Alzstatin, and Painless research platforms.

Its products pipeline includes ACD856 for the treatment of Alzheimer's disease, sleep disorders, depression, traumatic brain injuries, and Parkinson's disease, which is in phase I clinical trial; ACD857 and ACD680 that are in preclinical trial for the treatment of Alzheimer's disease; ACD440, a TRPV1 antagonist, which is in phase II clinical trial for neuropathic pain indications; and ACD137 negative allosteric modulator (NAM) of TrkA receptors for osteoarthritic pain indications, which is in preclinical phase.

AlzeCure Pharma AB (publ) was founded in 2012 and is based in Huddinge, Sweden.

Stock analysis

AlzeCure Pharma (ALZCUR) currently trades at kr 6.46, while our estimate is kr 4.54, 30% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: kr 3.41 (bear) to kr 5.68 (bull), the price of kr 6.46 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 53/100 (solid quality), in the Healthcare sector.

Weak Growth: Revenue growth is weak, negative or inconsistent.

AlzeCure Pharma reported revenue of 0 SEK in FY2025 versus 0 SEK in FY2021. Reported net income was −47.7M SEK in FY2025.

Key figures

Market cap 891M SEK (≈ $90.3M) Micro · P/E ratio 21.5 · P/S ratio 9.15 · EPS (TTM) kr 0.3000 · Net margin 31.6% · Return on equity 62.9% · Return on assets (EBIT) −112% (5-year average) · Operating margin 82.4%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 75 out of 100 (low confidence).

What moves the price

The share trades about 23% below its 52-week high and 447% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −30%, ALZCUR screens richer than that median.

Fair Value

Bear kr 3.41 Fair Value kr 4.54 Bull kr 5.68
Price kr 6.46 · Downside -29.7%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 53/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 75
Are margins and returns getting better?
Cashflow 58
Do the profits arrive as real cash?
Financial strength 96
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 82
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 86
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 11/100
Revenue growth is weak, negative or inconsistent.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

ALZCUR screens overvalued: fair value 30% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare AlzeCure Pharma with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks

Beats the industry median on 6/11 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 53 · Top 25%
Fair Value upside −29.7% · Below median
Profitability
Return on equity (12 months) 62.9% · Top 25%
Return on assets −80.7% · Bottom 25%
Net margin (12 months) 31.6% · Top 25%
Operating margin (12 months) 82.4% · Top 25%
Growth and dividend
Revenue growth (quarter YoY) 0.0% · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/E (12 months) 21.5× · Cheaper than median
P/B 27.06× · Priciest 25%
P/S (12 months) 9.15× · Pricier than median
EV/EBITDA 26.7× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)100 · sector 0
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 20

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs ALZCUR
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs ALZCUR
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs ALZCUR
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs ALZCUR
argenx SE ARGX $971.55 $908.40 −7% vs ALZCUR
CSL Limited CSL A$201.68 A$181.40 −10% vs ALZCUR
Moderna, Inc MRNA $250.83 $158.70 −37% vs ALZCUR
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs ALZCUR
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs ALZCUR
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs ALZCUR

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

AlzeCure Pharma: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "AlzeCure Pharma Fair Value". https://www.fairvalue-calculator.com/stock/ALZCUR

Frequently asked questions

Is AlzeCure Pharma (ALZCUR) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is kr 4.54 versus a price of kr 6.46, about 30% lower (overvalued).
What is the fair value of ALZCUR?
Our estimate for AlzeCure Pharma is kr 4.54 (as of Nov 10, 2026), built from audited fundamentals. The current price: kr 6.46.
What is the quality score of ALZCUR?
AlzeCure Pharma has a Quality Score of 53/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for AlzeCure Pharma (ALZCUR)?
Our calculated price target is the estimate of kr 4.54 (as of Nov 10, 2026). Cautious scenario kr 3.41, optimistic scenario kr 5.68. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the AlzeCure Pharma stock forecast for 2026?
Our estimate puts fair value at kr 4.54, about 30% lower versus a price of kr 6.46 (overvalued). Cautious scenario kr 3.41, optimistic scenario kr 5.68. The calculation is refreshed regularly with new filings.
What is the revenue of AlzeCure Pharma (ALZCUR)?
AlzeCure Pharma reported trailing-twelve-month revenue of about 97.3M SEK (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of AlzeCure Pharma (ALZCUR)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For AlzeCure Pharma it is kr 4.54 per share (as of Nov 10, 2026), against a price of kr 6.46.
Is AlzeCure Pharma stock overvalued or undervalued in 2026?
As of Nov 10, 2026, ALZCUR trades above its calculated fair value: price kr 6.46, fair value kr 4.54, a gap of about −30% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ALZCUR?
No. The price is what the market pays today (kr 6.46); the fair value is what the company's own numbers justify (kr 4.54). For AlzeCure Pharma the two are kr 1.92 per share apart. That gap is exactly why we show both numbers side by side.
How much is AlzeCure Pharma worth?
The market values AlzeCure Pharma at about 891M SEK (market capitalisation, as of Nov 10, 2026). Per share that is kr 6.46; our models calculate a fair value of kr 4.54 per share.
What do the bullish and bearish scenarios say about ALZCUR?
Our models span a range for AlzeCure Pharma: cautious scenario kr 3.41, base kr 4.54, optimistic kr 5.68 per share (as of Nov 10, 2026, price kr 6.46). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of ALZCUR?
AlzeCure Pharma trades at a price-to-earnings ratio of 21.5 (as of Nov 10, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of kr 4.54 is built from several models across several years. Other multiples: P/B 27.1, P/S 9.2, EV/EBITDA 26.7.
How solid is the balance sheet of AlzeCure Pharma (ALZCUR)?
Balance-sheet figures for AlzeCure Pharma (as of Nov 10, 2026): return on equity 62.9%. They feed the Quality Score of 53/100, which measures business quality independently of the share price.
How far is ALZCUR from its 52-week high?
AlzeCure Pharma trades at kr 6.46, about 23% below its 52-week high of kr 8.44 and 447% above the low of kr 1.18 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of kr 4.54 is for.
Which stocks are comparable to AlzeCure Pharma?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is AlzeCure Pharma stock attractive at the current price?
The data as of Nov 10, 2026: price kr 6.46, calculated fair value kr 4.54 (−30%), Quality Score 53/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. AlzeCure Pharma itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of AlzeCure Pharma (ALZCUR)?
The closing price on Nov 10, 2026 was kr 6.46. Our estimate is kr 4.54, about 30% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with AlzeCure Pharma right now?
The price sits above even our optimistic bull case (kr 5.68). The favourable scenario is already priced in. Solid but not exceptional quality (53/100) and above fair value, neither a clear bargain nor a standout compounder. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of AlzeCure Pharma

How large is the market capitalisation of AlzeCure Pharma (ALZCUR)?
The market capitalisation of AlzeCure Pharma is 891M SEK (≈ $90.3M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of AlzeCure Pharma (ALZCUR)?
The price-to-sales ratio of AlzeCure Pharma is 9.15 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of AlzeCure Pharma (ALZCUR)?
Earnings per share at AlzeCure Pharma are kr 0.3000 (price ÷ EPS = P/E 21.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of AlzeCure Pharma (ALZCUR)?
The net margin of AlzeCure Pharma is 31.6% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of AlzeCure Pharma (ALZCUR)?
The return on equity (ROE) of AlzeCure Pharma is 62.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of AlzeCure Pharma (ALZCUR)?
On an EBIT basis the return on assets of AlzeCure Pharma is −112% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of AlzeCure Pharma (ALZCUR)?
The operating margin of AlzeCure Pharma is 82.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How much free cash flow does AlzeCure Pharma (ALZCUR) generate?
The free cash flow of AlzeCure Pharma is −34.6M SEK (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does AlzeCure Pharma (ALZCUR) hold?
AlzeCure Pharma holds more cash than debt, 45.2M SEK net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch AlzeCure Pharma in the live analysis

One click puts AlzeCure Pharma on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.